Advaxis to Present at the BIO International Convention

Advaxis to Present at the BIO International Convention

<0> Advaxis, Inc.Diana Moore, 609-452-9814Director, Investor Relations & Business Development </0>

.) (“Advaxis” or the “Company”), a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announced that Daniel J. O’Connor, Senior VP, Chief Legal, and Business Development Officer at Advaxis, will present at the BIO International Convention (BIO 2013) on April 22 at 3:00 p.m. at the McCormick Place Convention Center in Chicago, IL. Mr. O’Connor will provide a review of the progress of the Company’s lead drug candidate, ADXS-HPV. Updated data regarding ADXS-HPV will be disclosed at the 2013 American Society of Clinical Oncology Annual Meeting in June.

The Convention is the largest global event for biotechnology and pharmaceutical industries that attract many of the biggest names across all major continents. BIO 2013 will provide key networking and partnering opportunities, as well as generate insights and inspirations on current trends that are essential in the development of innovative and better technologies for the future.

Advaxis is a clinical-stage biotechnology company developing the next generation of immunotherapies for cancer and infectious diseases. Advaxis immunotherapies are based on a novel platform technology using live, attenuated bacteria that are bio-engineered to secrete antigen/adjuvant fusion protein(s) designed to redirect the powerful immune response all human beings have to the bacteriumto the cancer itself.

ADXS-HPV is currently being evaluated in 5 clinical trials for human papillomavirus, or HPV, associated diseases: recurrent/refractory cervical cancer (India), locally advanced cervical cancer (GOG/NCI US study, Clinical Trials.gov Identifier NCT01266460), CIN 2/3 (U.S. study, Clinical Trials.gov Identifier NCT01116245), head & neckcancer (CRUK study, Clinical Trials.gov Identifier NCT01598792), and anal cancer (BrUOG study, Clinical Trial.gov Identifier NCT01671488). Over fifteen (15) distinct constructs are in various stages of development, developed directly by the Company and through strategic collaborations with recognized centers of excellence such as: the , , the , the , the , the , and others.

For more information please visit: | |

,

Suggested Articles

It’s been a minute, but AstraZeneca has gotten the FDA’s all-clear to restart the U.S. study of its COVID-19 vaccine.

Combining KSQ's USP1 inhibitor with Merck and AstraZeneca's PARP inhibitor Lynparza was more effective in animal models than either drug on its own.

Solid Bio is teaming up with Ultragenyx on Duchenne muscular dystrophy in a deal worth $40 million upfront but could net it another $255 million.